Aimei Health Tech's Net Income Halves Amid SPAC Extension Costs

TL;DR

**AFJKR is bleeding cash and running out of time; this SPAC is a hard pass unless you love high-stakes gambles.**

AI Summary

Aimei Health Technology Co., Ltd. (AFJKR) reported a net income of $352,019 for the three months ended September 30, 2025, a significant decrease from $743,510 in the same period of 2024. For the nine months ended September 30, 2025, net income was $961,651, down from $2,108,102 in the prior year, primarily due to a reduction in interest earned on cash held in trust, which fell from $2,770,867 in 2024 to $1,546,821 in 2025. The company, a blank check company, has not yet commenced operations and its activities are limited to costs in pursuit of an initial business combination. Total assets decreased from $73,814,933 as of December 31, 2024, to $45,468,518 as of September 30, 2025, largely due to redemptions of ordinary shares. Current liabilities increased substantially from $816,994 to $2,774,428, driven by an increase in extension loans from related parties to $1,655,400 and amounts due to a related company reaching $826,419. The company has extended its business combination deadline twelve times, now set for December 6, 2025, and faces risks related to completing a merger with United Hydrogen Group Inc. before this deadline.

Why It Matters

Aimei Health Technology's declining net income and substantial share redemptions signal significant challenges for its proposed merger with United Hydrogen Group Inc. Investors face increased uncertainty as the company repeatedly extends its deadline, diluting potential returns and raising questions about deal viability. Employees and customers of a potential target might see instability, while the broader SPAC market could view this as another example of a blank-check company struggling to execute, potentially dampening future SPAC enthusiasm and increasing scrutiny from regulators like the SEC. The competitive landscape for healthcare innovation SPACs remains fierce, and Aimei's prolonged search and financial shifts could make it less attractive.

Risk Assessment

Risk Level: high — The company's cash balance plummeted from $28,208 at December 31, 2024, to $2,979 at September 30, 2025, indicating severe liquidity issues. Furthermore, the accumulated deficit grew from $(1,476,823) to $(3,439,693) over the same period, reflecting ongoing operational losses and the financial strain of repeated extensions and redemptions, with $31.27 million in shares redeemed on February 5, 2025.

Analyst Insight

Investors should avoid AFJKR given its rapidly diminishing cash, increasing liabilities, and repeated extensions for a business combination. The significant share redemptions and growing accumulated deficit suggest a high probability of further value erosion or even liquidation if the United Hydrogen merger fails to close by December 6, 2025.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$45,468,518

total Debt

$3,464,428

net Income

$961,651

eps

$0.15

gross Margin

N/A

cash Position

$2,979

revenue Growth

N/A

Key Numbers

• $961,651 — Net Income (9 months) (Decreased from $2,108,102 in 2024, a 54.4% decline year-over-year.)
• $2,979 — Cash Balance (Significantly reduced from $28,208 at December 31, 2024, indicating severe liquidity issues.)
• $45,443,570 — Cash held in Trust Account (Decreased from $73,784,549 at December 31, 2024, due to share redemptions.)
• $3,439,693 — Accumulated Deficit (Increased from $1,476,823 at December 31, 2024, reflecting growing losses.)
• $1,655,400 — Extension loans– related party (Increased from $227,700 at December 31, 2024, highlighting reliance on related party funding for extensions.)
• 3,995,733 — Ordinary shares subject to possible redemption (Reduced from 6,900,000 shares at December 31, 2024, due to redemptions.)
• $31,265,500 — Cash withdrawn from Trust Account (Used for redemptions in connection with the February 5, 2025, stockholder vote.)
• 12 — Number of extensions (The company has extended its business combination deadline twelve times, pushing it to December 6, 2025.)

Key Players & Entities

• Aimei Health Technology Co., Ltd. (company) — registrant of the 10-Q filing
• Aimei Investment Ltd (company) — Company's sponsor and representative for shareholders
• United Hydrogen Group Inc. (company) — target for business combination
• Continental Stock Transfer & Trusts Company (company) — Trustee for the Investment Management Trust Agreement
• SEC (regulator) — U.S. Securities and Exchange Commission
• $352,019 (dollar_amount) — Net income for the three months ended September 30, 2025
• $961,651 (dollar_amount) — Net income for the nine months ended September 30, 2025
• $2,979 (dollar_amount) — Cash balance as of September 30, 2025
• $1,655,400 (dollar_amount) — Extension loans from related party as of September 30, 2025
• $31.27 million (dollar_amount) — Aggregate amount of shares redeemed on February 5, 2025

FAQ

Risk Factors

• Dependence on Trust Account and Shareholder Redemptions [high — financial]: The company's cash position is heavily reliant on its Trust Account, which decreased from $73,784,549 as of December 31, 2024, to $45,443,570 as of September 30, 2025, due to significant share redemptions totaling $31,265,500. This trend indicates a potential liquidity crunch if redemptions continue or if a business combination is not consummated, impacting the company's ability to fund operations and pursue its objectives.
• Failure to Complete Business Combination [high — operational]: Aimei Health Technology has extended its business combination deadline twelve times, with the current deadline set for December 6, 2025. The company faces substantial risk in completing a merger with United Hydrogen Group Inc. before this deadline. Failure to do so could result in the liquidation of the company and the return of funds held in trust to shareholders, rendering the company's efforts to date unsuccessful.
• Increasing Reliance on Related Party Financing [medium — financial]: Total current liabilities have surged from $816,994 to $2,774,428, largely driven by an increase in extension loans from related parties to $1,655,400 (up from $227,700) and amounts due to a related company reaching $826,419. This escalating debt to related parties highlights a growing dependence on internal funding to sustain operations and extensions, which may not be sustainable long-term.
• Declining Interest Income and Net Income [medium — financial]: Net income for the nine months ended September 30, 2025, was $961,651, a significant decrease of 54.4% from $2,108,102 in the prior year. This decline is primarily attributed to a reduction in interest earned on cash held in trust, which fell from $2,770,867 in 2024 to $1,546,821 in 2025, reflecting lower cash balances and potentially lower interest rates.
• Growing Accumulated Deficit [low — financial]: The company's accumulated deficit has increased from $1,476,823 as of December 31, 2024, to $3,439,693 as of September 30, 2025. This indicates that operating costs and other expenses have continued to outpace any revenue or income generated, a common characteristic of blank check companies before a business combination.

Industry Context

Aimei Health Technology operates as a blank check company, a segment of the financial services industry focused on facilitating mergers and acquisitions. The competitive landscape for SPACs is characterized by a race against time to identify and complete a viable business combination before their deadlines expire. Industry trends include increasing regulatory scrutiny and a growing emphasis on the quality and strategic fit of target companies.

Regulatory Implications

As a blank check company, Aimei Health Technology is subject to SEC regulations governing IPOs, disclosures, and SPAC operations. The repeated extensions and the potential for liquidation carry regulatory implications, particularly concerning investor protection and the proper use of funds held in trust. Compliance with reporting requirements for its ongoing pursuit of a business combination is paramount.

What Investors Should Do

1. Monitor the progress of the business combination with United Hydrogen Group Inc.
2. Assess the company's liquidity and cash burn rate.
3. Evaluate the terms and feasibility of the proposed merger with United Hydrogen Group Inc.

Key Dates

• 2025-12-06: Business Combination Deadline — This is the final deadline for Aimei Health Technology to complete its initial business combination. Failure to meet this deadline will likely result in the liquidation of the company.
• 2025-02-05: Stockholder Vote on Extension — Shareholders voted on extending the business combination deadline, leading to significant redemptions of ordinary shares and a substantial withdrawal of funds from the Trust Account.

Glossary

Blank Check Company

A shell corporation that is established to raise capital through an initial public offering (IPO) for the purpose of acquiring or merging with an existing company. These companies have no commercial operations and are often referred to as 'SPACs' (Special Purpose Acquisition Companies). (Aimei Health Technology is a blank check company, meaning its financial activities and risks are centered around finding and completing a business combination.)

Cash held in Trust Account

Funds raised by a blank check company during its IPO that are held in a trust account and can only be used for a business combination or to redeem shares if the combination is not completed. Interest earned on these funds is typically used to extend the company's deadline. (This account represents the vast majority of the company's assets and is critical for its existence and ability to complete a merger.)

Ordinary shares, subject to possible redemption

Shares issued by a blank check company that give holders the right to have their shares redeemed for cash from the trust account if they do not approve of a proposed business combination or if the company fails to complete one by a certain deadline. (The number of these shares and their redemption value directly impact the company's cash position and the amount available for a business combination.)

Accumulated deficit

The cumulative net losses of a company that have not been offset by net income. It represents the total losses incurred since the company's inception. (An increasing accumulated deficit, as seen in Aimei Health Technology, is typical for pre-operational companies and indicates ongoing expenses without corresponding revenue.)

Extension loans– related party

Loans provided by individuals or entities closely associated with the company's management or sponsors, often used to extend the deadline for completing a business combination. These loans are typically unsecured and may be convertible into equity or repaid from funds not held in trust. (The significant increase in these loans highlights the company's reliance on related parties to fund its extended timeline and operational costs.)

Year-Over-Year Comparison

Compared to the prior year, Aimei Health Technology has experienced a significant decline in financial performance. Net income for the nine months ended September 30, 2025, dropped by 54.4% to $961,651, primarily due to a decrease in interest income from its trust account. Total assets have also fallen sharply from $73,814,933 to $45,468,518, driven by substantial share redemptions. Concurrently, current liabilities have more than tripled, increasing from $816,994 to $2,774,428, largely due to increased borrowing from related parties, indicating a deteriorating financial position and increased operational risk.

Key Financial Figures

• $0.0001 — registered Ordinary Shares, par value $0.0001 per share AFJK The Nasdaq Stock Mar

Filing Documents

• form10-q.htm (10-Q) — 575KB
• ex31-1.htm (EX-31.1) — 13KB
• ex31-2.htm (EX-31.2) — 13KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• 0001493152-25-024062.txt ( ) — 3365KB
• afjk-20250930.xsd (EX-101.SCH) — 23KB
• afjk-20250930_cal.xml (EX-101.CAL) — 25KB
• afjk-20250930_def.xml (EX-101.DEF) — 139KB
• afjk-20250930_lab.xml (EX-101.LAB) — 190KB
• afjk-20250930_pre.xml (EX-101.PRE) — 172KB
• form10-q_htm.xml (XML) — 474KB

Financial Statements

Financial Statements 1 Unaudited Balance Sheets as of September 30, 2025 and December 31, 2024 1 Unaudited Statements of Operations for the three and nine months ended September 30, 2025 and 2024 2 Unaudited Statements of Changes in Shareholders' Deficit for the three and nine months ended September 30, 2025 and 2024 3 Unaudited Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 4 Notes to Unaudited Financial Statements 5 Item 2

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 17 Item 3

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 19 Item 4

Controls and Procedures

Controls and Procedures 19 Part II Other Information 20 Item 1

Legal Proceedings

Legal Proceedings 20 Item 1A

Risk Factors

Risk Factors 20 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 20 Item 3 Defaults Upon Senior Securities 20 Item 4 Mine Safety Disclosures 21 Item 5 Other Information 21 Item 6 Exhibits 21 Signature 22 i AIMEI HEALTH TECHNOLOGY CO., LTD PART I - FINANCIAL INFORMATION Item 1. Financial Statements AIMEI HEALTH TECHNOLOGY CO., LTD UNAUDITED BALANCE SHEETS September 30, 2025 December 31, 2024 ASSETS Current assets: Cash $ 2,979 $ 28,208 Prepaid expenses 21,969 2,176 Total current assets 24,948 30,384 Cash held in Trust Account 45,443,570 73,784,549 TOTAL ASSETS $ 45,468,518 $ 73,814,933 LIABILITIES, TEMPORARY EQUITY AND SHAREHOLDERS' DEFICIT Current liabilities: Accrued expenses $ 292,609 $ 299,514 Extension loans– related party 1,655,400 227,700 Due to a related company 826,419 289,780 Total current liabilities 2,774,428 816,994 Deferred underwriter fee payable 690,000 690,000 TOTAL LIABILITIES 3,464,428 1,506,994 Commitments and contingencies (Note 7) - - Ordinary shares, subject to possible redemption, 3,995,733 and 6,900,000 shares issued and outstanding at redemption value of $ 11.37 and $ 10.69 , as of September 30, 2025 and December 31, 2024, respectively 45,443,570 73,784,549 Shareholders' deficit: Ordinary shares, $ 0.0001 par value; 500,000,000 shares authorized; 2,126,000 and 2,126,000 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively (excluding 3,995,733 and 6,900,000 shares subject to possible redemption, respectively) 213 213 Accumulated deficit ( 3,439,693 ) ( 1,476,823 ) Total shareholders' deficit ( 3,439,480 ) ( 1,476,610 ) TOTAL LIABILITIES, TEMPORARY EQUITY AND SHAREHOLDERS' DEFICIT $ 45,468,518 $ 73,814,933 The accompanying notes are an integral part of these unaudited financial statements. 1 AIMEI HEALTH TECHNOLOGY CO., LTD UNAUDITED For

View Full Filing

View this 10-Q filing on SEC EDGAR